Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.

@article{Valcarcel2015UseON,
  title={Use of newer prognostic indices for patients with myelodysplastic syndromes in the low and intermediate-1 risk categories: a population-based study.},
  author={D Valcarcel and Guillermo Sanz and Margarita Ortega and Benet Nomdedeu and Elisa Lu{\~n}o and Mar{\'i}a D{\'i}ez-Campelo and Mar{\'i}a Teresa Ardanaz and Carmen Pedro and Julia Montoro and Rosa Collado and Rafa Andreu and V{\'i}ctor Marco and Mar{\'i}a Teresa Cedena and Raquel de Paz and Mar Tormo and Blanca Xicoy and Fernando Ramos and Joan Bargay and B. J. Gonz{\'a}lez and Salut Brunet and Juan Antonio Mu{\~n}oz and Valle G{\'o}mez and Alicia Bail{\'e}n and Joaquin Susmozas S{\'a}nchez and Brayan Merch{\'a}n and Consuelo del Ca{\~n}izo and Teresa Vallesp{\'i}},
  journal={The Lancet. Haematology},
  year={2015},
  volume={2 6},
  pages={e260-6}
}
BACKGROUND We aimed to compare the ability of recently developed prognostic indices for myelodysplastic syndromes to identify patients with poor prognoses within the lower-risk (low and intermediate-1) categories defined by the International Prognosis Scoring System (IPSS). METHODS We included patients with de-novo myelodysplastic syndromes diagnosed between Nov 29, 1972, and Dec 15, 2011, who had low or intermediate-1 IPSS scores and were in the Spanish Registry of Myelodysplastic Syndromes… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS